Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GPCR |
---|---|---|
09:32 ET | 16085 | 41.51 |
09:34 ET | 17404 | 42.03 |
09:36 ET | 100 | 42.03 |
09:38 ET | 1195 | 42.379 |
09:39 ET | 1984 | 42.455 |
09:41 ET | 2150 | 42.49 |
09:43 ET | 779 | 42.4 |
09:45 ET | 1400 | 42.205 |
09:48 ET | 100 | 42.205 |
09:50 ET | 1950 | 42.16 |
09:52 ET | 1311 | 42.115 |
09:54 ET | 6915 | 42.1 |
09:56 ET | 300 | 42.01 |
09:57 ET | 1900 | 42.08 |
09:59 ET | 976 | 42.08 |
10:01 ET | 1400 | 42.02 |
10:03 ET | 13670 | 42.18 |
10:06 ET | 13700 | 42.475 |
10:08 ET | 8800 | 42.59 |
10:10 ET | 1434 | 42.7014 |
10:12 ET | 1170 | 42.78 |
10:14 ET | 988 | 42.79 |
10:15 ET | 350 | 42.85 |
10:17 ET | 1195 | 42.84 |
10:19 ET | 2735 | 43.115 |
10:21 ET | 3739 | 43.37 |
10:24 ET | 3100 | 43.06 |
10:26 ET | 800 | 43.1299 |
10:28 ET | 1850 | 43 |
10:30 ET | 625 | 43.165 |
10:32 ET | 801 | 43.35 |
10:33 ET | 3300 | 43.51 |
10:35 ET | 2721 | 43.88 |
10:37 ET | 1756 | 43.7133 |
10:39 ET | 850 | 43.51 |
10:42 ET | 1800 | 43.25 |
10:44 ET | 1382 | 43.34 |
10:46 ET | 300 | 43.335 |
10:48 ET | 538 | 43.335 |
10:50 ET | 2218 | 43.48 |
10:51 ET | 3582 | 43.47 |
10:53 ET | 1550 | 43.49 |
10:55 ET | 1332 | 43.44 |
10:57 ET | 4685 | 43.44 |
11:00 ET | 1983 | 43.45 |
11:02 ET | 1321 | 43.45 |
11:04 ET | 1000 | 43.42 |
11:06 ET | 550 | 43.46 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Structure Therapeutics Inc | 2.4B | -19.4x | --- |
SpringWorks Therapeutics Inc | 2.4B | -7.4x | --- |
Verona Pharma PLC | 2.4B | -18.7x | --- |
CG Oncology Inc | 2.5B | -31.5x | --- |
Vera Therapeutics Inc | 2.3B | -19.2x | --- |
Immunitybio Inc | 2.5B | -3.9x | --- |
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.24 |
Book Value | $9.76 |
P/E Ratio | -19.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.